Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more
Percheron Therapeutics Limited (PERCF) - Net Assets
Latest net assets as of June 2025: $10.00 Million USD
Based on the latest financial reports, Percheron Therapeutics Limited (PERCF) has net assets worth $10.00 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.44 Million) and total liabilities ($2.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.00 Million |
| % of Total Assets | 80.44% |
| Annual Growth Rate | -22.07% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.62 |
Percheron Therapeutics Limited - Net Assets Trend (2022–2025)
This chart illustrates how Percheron Therapeutics Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Percheron Therapeutics Limited (2022–2025)
The table below shows the annual net assets of Percheron Therapeutics Limited from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $10.00 Million | +6.84% |
| 2024-06-30 | $9.36 Million | -6.14% |
| 2023-06-30 | $9.98 Million | -52.81% |
| 2022-06-30 | $21.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Percheron Therapeutics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2275766900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $113.67 Million | 1136.27% |
| Total Equity | $10.00 Million | 100.00% |
Percheron Therapeutics Limited Competitors by Market Cap
The table below lists competitors of Percheron Therapeutics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ojai Oil Company
PINK:OJOC
|
$3.12 Million |
|
Megapower Makmur TBK PT
JK:MPOW
|
$3.12 Million |
|
Pioneer Embroideries Limited
NSE:PIONEEREMB
|
$3.12 Million |
|
Yggdrazil Group Public Company Limited
BK:YGG
|
$3.12 Million |
|
Solargiga Energy Holdings Limited
PINK:SEHLF
|
$3.12 Million |
|
Meta Epsi Tbk PT
JK:MTPS
|
$3.12 Million |
|
Upco International Inc
PINK:UCCPF
|
$3.12 Million |
|
Equinox Resources Ltd
AU:EQN
|
$3.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Percheron Therapeutics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,363,087 to 10,003,873, a change of 640,786 (6.8%).
- Net loss of 14,921,913 reduced equity.
- Share repurchases of 864,690 reduced equity.
- New share issuances of 14,871,491 increased equity.
- Other factors increased equity by 1,555,898.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.92 Million | -149.16% |
| Share Repurchases | $864.69K | -8.64% |
| Share Issuances | $14.87 Million | +148.66% |
| Other Changes | $1.56 Million | +15.55% |
| Total Change | $- | 6.84% |
Book Value vs Market Value Analysis
This analysis compares Percheron Therapeutics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.43x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.13x to 0.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | $0.03 | $0.00 | x |
| 2023-06-30 | $0.01 | $0.00 | x |
| 2024-06-30 | $0.01 | $0.00 | x |
| 2025-06-30 | $0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Percheron Therapeutics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -149.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-149.16%) is below the historical average (-104.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -27.49% | 0.00% | 0.00x | 1.06x | $-7.93 Million |
| 2023 | -114.08% | 0.00% | 0.00x | 1.29x | $-12.38 Million |
| 2024 | -127.30% | 0.00% | 0.00x | 1.55x | $-12.86 Million |
| 2025 | -149.16% | 0.00% | 0.00x | 1.24x | $-15.92 Million |
Industry Comparison
This section compares Percheron Therapeutics Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Percheron Therapeutics Limited (PERCF) | $10.00 Million | -27.49% | 0.24x | $3.12 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |